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Abstract. 
 
Glypicans are a family of heparan sulfate 
proteoglycans that are linked to the cell surface 
through a glycosyl–phosphatidylinositol anchor. One 
member of this family, 
 
glypican-3
 
 (
 
Gpc3)
 
, is mutated in 
patients with the Simpson-Golabi-Behmel syndrome 
(SGBS). These patients display pre- and postnatal over-
growth, and a varying range of dysmorphisms. The clin-
ical features of SGBS are very similar to the more ex-
tensively studied Beckwith-Wiedemann syndrome 
(BWS). Since BWS has been associated with biallelic 
expression of insulin-like growth factor II (IGF-II), it 
has been proposed that GPC3 is a negative regulator of 
IGF-II. However, there is still no biochemical evidence 
indicating that GPC3 plays such a role.
Here, we report that GPC3-deﬁcient mice exhibit 
several of the clinical features observed in SGBS pa-
tients, including developmental overgrowth, perinatal 
death, cystic and dyplastic kidneys, and abnormal lung 
development. A proportion of the mutant mice also dis-
play mandibular hypoplasia and an imperforate vagina. 
In the particular case of the kidney, we demonstrate 
that there is an early and persistent developmental ab-
normality of the ureteric bud/collecting system due to 
increased proliferation of cells in this tissue element.
The degree of developmental overgrowth of the 
GPC3-deﬁcient mice is similar to that of mice deﬁcient 
in IGF receptor type 2 (IGF2R), a well characterized 
negative regulator of IGF-II. Unlike the IGF2R-deﬁ-
cient mice, however, the levels of IGF-II in GPC3 
knockouts are similar to those of the normal litter-
mates.
Key words: glypican-3 • Simpson-Golabi-Behmel 
syndrome • overgrowth • insulin-like growth factor II • 
kidney dysplasia
 
G
 
LYPICANS
 
 are a family of heparan sulfate (HS)
 
1
 
proteoglycans that are linked to the cell surface
through a glycosyl–phosphatidylinositol anchor
(David, 1993; Stipp et al., 1994; Filmus et al., 1995; Nakato
et al., 1995; Watanabe et al., 1995; Veugelers et al., 1997).
The protein cores of glypicans are 20–50% identical. In
particular, the location of 13 cysteines and of the consen-
sus sites for the insertion of the HS chains are highly con-
served (Saunders et al., 1997). The function of glypicans is
still not well understood. Regulatory mutations of 
 
dally
 
(division abnormally delayed), a 
 
Drosophila
 
 glypican,
have a severe impact on the postembryonic development
of the nervous system, and generate morphological defects
in the eyes, antennae, wings, and genitalia (Nakato et al.,
1995). Recently, it has been reported that 
 
dally
 
 controls
cellular responses to decapentaplegic, but the molecular
basis of this activity is unknown (Jackson et al., 1997).
Glypican-1 (GPC1), on the other hand, has the capacity to
interact and regulate the activity of fibroblast growth fac-
tor-2 and other heparin-binding growth factors in tissue
culture (Steinfeld et al., 1996; Bonneh-Barkay et al., 1997;
Kleef et al., 1998). The interaction of GPC1 and these
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growth factors is mediated by its HS chains, suggesting
that GPC1 is regulating the binding of the growth factors
to their high affinity receptors (Steinfeld et al., 1996).
Recent work by Pilia et al. (1996) has demonstrated that
the
 
 glypican-3
 
 (
 
Gpc3
 
) gene is mutated in patients with the
Simpson-Golabi-Behmel syndrome (SGBS). This is an
X-linked disorder in which patients display pre- and post-
natal overgrowth, and a varying range of dysmorphisms
that can include a distinct facial appearance, macroglossia,
cardiac defects, dysplastic and cystic kidneys, hernias, su-
pernumerary nipples, and various skeletal abnormalities,
including polydactyly and syndactyly (Behmel et al., 1984;
Neri et al., 1988; Garganta and Bodurtha, 1992; Orstavik
et al., 1995; Pilia et al., 1996; Lindsay et al., 1997). Death
during infancy is very frequent, usually as a result of pneu-
monia (Garganta et al., 1992). The clinical features of
SGBS suggest that GPC3 is involved in the regulation
of cell proliferation and apoptosis during development
(Hughes-Benzie et al., 1996). Indeed, we have recently
demonstrated that GPC3 can induce apoptosis or inhibit
proliferation in a cell-line–specific manner (Dueñas Gon-
zales et al., 1998; Filmus, J., unpublished observations). It
is also important to note that GPC3 is highly expressed
during development in the tissues that are affected in
SGBS patients (Pellegrini et al., 1998).
SGBS is phenotypically very similar to the more ex-
tensively studied Beckwith-Wiedemann syndrome (BWS;
Weksberg et al., 1996; Hastie, 1997). Since biallelic expres-
sion of the paternally imprinted 
 
insulin-like growth factor-
II (Igf2)
 
 gene is thought to play a prominent role in BWS
(Brown et al., 1996; Weksberg and Squire, 1996; Sun et al.,
1997), it has been proposed that GPC3 is a negative regu-
lator of this growth factor (Pilia et al., 1996). Additional
indirect evidence suggesting that GPC3 can act as a nega-
tive regulator of IGF-II has been provided recently by the
generation of double mutant mice lacking the IGF recep-
tor type 2 (IGF2R), and the 
 
H19 
 
locus (Eggenschwiler et
al., 1997). IGF2R is a well characterized negative regulator
of IGF-II that binds this growth factor and downregulates
its activity by endocytosis and degradation (Ludwig et al.,
1996). Meanwhile, the 
 
H19
 
 locus regulates IGF-II imprint-
ing. Consequently, when this locus is deleted, 
 
Igf2 
 
imprint-
ing is suppressed, and biallelic expression is observed
(Leighton et al., 1995). As expected, the 
 
Igf2r
 
 and 
 
H19
 
double mutants display a dramatic increase in circulating
and tissue IGF-II levels (Eggenschwiler et al., 1997). In ad-
dition, these mice exhibit some of the clinical features of
BWS, including developmental overgrowth, viscerome-
galy, omphalocele, and cardiac, and adrenal defects. Inter-
estingly, skeletal defects that are more typical of SGBS are
also observed in these double mutants (Weksberg et al.,
1996).
Despite these indirect genetic data suggesting that
GPC3 plays a role IGF-II signaling, it is important to note
that conclusive biochemical data supporting such a role for
GPC3 has not been provided. Therefore, we have gener-
ated GPC3-deficient mice in an effort to study SGBS and
the molecular basis of its similarity to BWS. We report
here that these mice display many of the phenotypic fea-
tures of SGBS, including developmental overgrowth,
perinatal death, abnormal lung development, and cystic
kidneys. Developmental overgrowth, however, was not ac-
companied by higher levels of circulating IGF-II or by a
significantly increased expression of this growth factor in
tissues.
 
Materials and Methods
 
Targeting Vector
 
A 6.5-kb portion of the 
 
Gpc3
 
 gene was cloned by screening a 129J-1 Dash
II genomic library with the 5
 
9
 
 end of the 
 
Gpc3
 
 cDNA. A SmaI fragment
within the 6.5-kb genomic clone that included part of the promoter region
and exon 1 was replaced by an EcoRI/BglII fragment containing the neo-
mycin-resistance gene under the control of the PGK promoter, driving ex-
pression in the antisense direction (neo cassette). The final targeting vec-
tor carried the PGK–neo cassette flanked by part of the 
 
Gpc3
 
 promoter
and the first intron at the 5
 
9
 
 and 3
 
9
 
 ends, respectively (Fig. 1 A). The vec-
tor was linearized and used to electroporate 129/J embryonic stem (ES)
cells. Transfected clones resistant to G418 were screened by PCR for ho-
mologous recombination. Two recombinant ES clones, 8D1 and 7F12,
were then used for injections into C57BL/6 blastocysts. Germline trans-
mission was identified by Southern blot analysis of EcoRI-digested ge-
nomic DNA using a SmaI/KpnI fragment (S1) of the genomic clone. Mice
were subsequently genotyped using PCR as follows: the presence of the
neo cassette was determined by amplifying a neo-specific band using
primers PCR2 and neo, followed by primers PCRL2 and neo in nested
PCR reactions; a single denaturation step (95
 
8
 
C for 5 min) was followed
by 25 cycles (94
 
8
 
C for 2 min, 55
 
8
 
C for 2 min, and 72
 
8
 
C for 3 min), with a fi-
nal single elongation step (72
 
8
 
C for 5 min). To detect the 420-bp wild-type
fragment of the 
 
Gpc3
 
 gene to distinguish heterozygous and homozygous
mutants, primers PCRL3 and PCR5 were used in 25 cycles (94
 
8
 
C for 30 s,
55
 
8
 
C for 30 s, and 72
 
8
 
C for 30 s), followed by a final elongation step (72
 
8
 
C
for 5 min). Primers were: PCR2, 5
 
9
 
-GTGTGGTTCTATTGAATG-
GACCC-3
 
9
 
; neo, 5
 
9
 
-GCCAGCTCATTCCTCCACTCAT-3
 
9
 
; PCRL2, 5
 
9
 
-
ACGTGACTATTTGTGGGTAGG-3
 
9
 
; PCRL2, 5
 
9
 
-ACGTGACTATTT-
GTGGGTAGG-3
 
9
 
; PCRL3, 5
 
9
 
-TTGCCACTCTCTCGTGCTCTCC-3
 
9
 
;
and PCR5, 5
 
9
 
-CAGAGTCCATACTGTGCTTCC-3
 
9
 
.
 
Measurement of Embryonic Growth
 
For staging embryos, noon of the day of a vaginal plug was considered
E0.5. For weighing, embryos were dissected out of their yolk sacs and pat-
ted dry.
 
Measurements of IGF-II Levels
 
The quantification of IGF-II by Western blot was performed according to
a previously published method (Ludwig et
 
 
 
al., 1996). In brief, embryos
were homogenized in 1 M acetic acid and incubated for 1 h in ice. Homo-
genates were then spun at 15,000 rpm for 10 min and supernatants were
neutralized with 5 N NaOH. After spinning again at 15,000 rpm for 10
min, proteins were precipitated from the supernatant with trichloroacetic
acid (final concentration 20% vol/vol). Pellets were washed twice with
80% ethanol/100 mM Tris, pH 7.5, and were solubilized in SDS-PAGE
loading buffer. Protein concentration was determined using the BCA re-
agent (Pierce Chemical Co.). Typically, 20–50 
 
m
 
g of protein or 16 
 
m
 
l of se-
rum (previously diluted 1:3 with 1% SDS) were run on a 10–20% SDS-
PAGE gradient gel. Equal protein loading was confirmed by Coomassie
blue staining. Proteins were transferred to a PVDF membrane in a 10 mM
CAPS buffer, pH 11.0. Membranes were then incubated with 0.1 
 
m
 
g/ml of
an anti-rat IGF-II antibody (Amano) followed by an anti-mouse streptavi-
din-conjugated secondary antibody (Sigma Chemical Co.). Bound anti-
body was visualized using Biotin-HRP and chemiluminescence. The inten-
sity of the bands corresponding to IGF-II was measured with a scanning
densitometer (Molecular Dynamics, Inc.) and compared with the intensity
of bands corresponding to different amounts of recombinant IGF-II.
For Northern blot analysis, tissue extracts were prepared using a Poly-
tron. RNA was extracted using trizol (GIBCO BRL). After electro-
phoretic separation and transfer to a membrane, the RNA was probed
with mouse 
 
Igf2
 
 cDNA. To correct for equal loading, the membrane was
stripped and reprobed with a GAPDH cDNA. The intensity of the bands
corresponding to IGF-II and GAPDH was measured with a scanning den-
sitometer. 
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Histopathology
 
Whole embryos, excised organs, or pups that had been subjected to a mid-
line incision were fixed in 10% neutral buffered formalin at room temper-
ature overnight before paraffin embedding using standard histological
techniques. Paraffin blocks were sectioned at 5–6 
 
m
 
m and stained with he-
matoxylin and eosin. Embryonic skeletons were stained with Alcian blue
and Alizarin red S (Bullock et al., 1998).
 
Cell Proliferation and Apoptosis in Embryonic Kidney
 
Pregnant mice were injected intraperitoneally with 5 bromo-2
 
9
 
de-
oxyuridine (BrdU) 100 
 
m
 
g/g body weight. Embryos were surgically re-
moved 3 h later and kidneys were isolated and fixed in 4% formaldehyde
in PBS, pH 7.4. Paraffin-embedded kidney tissue sections were deparaf-
finized in xylene, rehydrated in a graded ethanol series, rinsed in PBS, and
then either processed further for BrdU staining or stained directly with
hematoxylin and eosin. Sections used for BrdU assays were treated with
trypsin for 5 min at 37
 
8
 
C and then processed for BrdU detection using
commercially available reagents (Boehringer Mannheim). To identify ure-
teric buds/collecting ducts, sections were stained for 1 h at room tempera-
ture with Dolichos Biflorus agglutinin (DBA; Vector Labs, Inc.) diluted
1:100 in blocking buffer consisting of 5% goat serum (Life Technologies,
Inc.), 3% BSA (ICN Biochemicals), and 0.01% Tween 20 (Sigma Chemi-
cal Co.) in PBS, pH 7.4. Sections were then dehydrated in a graded etha-
nol series, treated with xylene for 10 min, and mounted with DPX Moun-
tant (VWR Scientific).
BrdU-labeled E13 kidney tissue sections were imaged sequentially at
400
 
3
 
 by bright-field and fluorescence microscopy using an Axioskop mi-
croscope (Carl Zeiss) fitted with an HBO 50 W vapor short-arc lamp using
a Shott 38 band-pass filter and a 3-FL fluorescence reflector. Entire sec-
tions of renal tissue were reconstructed on the benchtop by building a
composite from the photographed images. The composite was analyzed by
counting the proportion of BrdU-labeled cells within the population of
ureteric bud/collecting duct cells (DBA positive) and mesenchymal cells
(DBA negative).
 
Results
 
Generation of GPC3-deficient Mice
 
To generate GPC3-deficient mice by homologous recom-
bination, a targeting construct designed to remove part of
the promoter region and the first exon of 
 
Gpc3
 
 (Fig. 1 A)
was transfected into 129/J ES cells. Several clones that
displayed homologous recombination were then injected
into C57BL/6 blastocysts. Since 
 
Gpc3
 
 is X-linked, the
backcrossing of F1 heterozygous females with wild-type
C57BL/6 males was expected to generate male null mu-
tants (
 
2
 
/). Indeed, that was the case, as shown by South-
ern blot analysis (Fig. 1 B). The lack of expression of
GPC3 in the 
 
2
 
/ mice was confirmed by Northern blot (Fig.
1 C). 226 F2 backcross mice were typed by PCR and 47
(21%) were found to be 
 
2
 
/. This is close to the 25% pre-
dicted by Mendelian inheritance, and evidence of embry-
onic lethality was not found. However, 10 of the 47 
 
Gpc3
 
 
 
2
 
/
mice died before weaning. After successive backcrossing
to C57BL/6, it became evident that the lack of GPC3 ex-
pression increasingly affected viability. For example, after
the fourth backcross (N4), only 21 (10%) of the mice that
could be typed (many were cannibalized) were hemizy-
gous mutants, and only two out of these 21 mice survived
to weaning. Similar perinatal lethality was observed when
the backcrossing was performed with Balb/c mice (data
not shown). By the eighth backcross (N8) in the C57BL/6
strain (almost congenic), all mice died perinatally. These
results indicate that the phenotype of 
 
Gpc3
 
 
 
2
 
/ mice is
highly dependent on the genetic background. Unless oth-
erwise indicated, all studies described were performed in
Figure 1. Gene targeting of the murine Gpc3 locus. (A) A 6.5-kb
EcoRI fragment of the murine Gpc3 locus is shown (top). The
SmaI fragment containing the promoter, the transcription start
site (arrow), exon 1, and part of intron 1 is indicated. An EcoRI/
Bg1II fragment containing the neo cassette, a neomycin gene
with a PGK promoter, driving expression in the antisense direc-
tion, is shown in the middle. The mutated locus with the neo cas-
sette replacing the SmaI fragment is shown below. Restriction
enzyme sites are as follows: E, EcoRI; K, KpnI; S, SmaI. The
probe (S1) hybridized to the 6.5-kb wild-type and 7.5-kb targeted
allele fragments, as expected. PCR primer sites and orientation
within the native and disrupted loci are indicated: a, PCRL3; b,
PCR5; c, PCR2; d, PCRL2; and e, neo. (B) Southern blot analysis
of EcoRI-digested genomic DNA extracted from tail biopsies of
wild-type, heterozygous, and hemizygous mutant offspring (1/1,
1/2, and 2/, respectively). (C) Top, Northern blot analysis of
GPC3 in wild-type (1/1) and (2/) E18.5 embryos. 10 mg total
RNA was probed with a 2.2-kb full-length Gpc3 cDNA. Bottom,
ethidium bromide staining demonstrates equal loading. 
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mice obtained from backcrosses 7 to 9 (N7 to N9) with the
C57BL/6 strain.
Anatomical examination of mice from N4 and succes-
sive backcrosses revealed the presence of cystic and dys-
plastic kidneys in all 
 
Gpc3
 
 
 
2
 
/ and some female 
 
Gpc3
 
 
 
1
 
/
 
2
 
mice (Fig. 2). These abnormalities were seen in a large
proportion of mice from earlier backcrosses, also. How-
ever, the degree of dysplasia varied significantly from
mouse to mouse.
As discussed above, a proportion of 
 
Gpc3
 
 
 
2
 
/ mice sur-
vived beyond the first day, particularly in earlier back-
crosses (N2 to N4). Many of these mice, however, died be-
fore weaning. Histological analysis revealed the presence
of bacterial infection in the respiratory tract (pneumonia
and rhinitis), as well as an accumulation of cellular debris
and mucus in small and medium size bronchioles. Al-
though there were no obvious differences between wild-
type and mutant mice at E18 (embryonic day 18; Fig. 3), as
early as P0 (postnatal day 0) the lumens of airways con-
tained an admixture of stranding mucus and sloughed epi-
thelial cells. By P5, the amount of mucus had increased
and was distributed over the entire surface of the respira-
tory epithelium. These lesions may have contributed to the
perinatal death and increased susceptibility of 
 
Gpc3
 
 
 
2
 
/
mice to respiratory infections.
In our initial examination of the newborn 
 
Gpc3
 
 
 
2
 
/ mice,
no obvious skeletal abnormalities were observed by X-ray
analysis or staining. However, when mutant embryos from
backcrosses N7 and N8 were examined, a proportion of
them (10%) were found to have severe mandibular hypo-
plasia (Fig. 4). Histological analysis of jaw sections re-
vealed no bone constituting the rami of the mandible,
which consisted only of myxomatous stroma with overly-
ing haired skin (data not shown).
To generate female 
 
Gpc3
 
 
 
2
 
/
 
2
 
 mice, the few 
 
Gpc3
 
 
 
2
 
/
mice that reached adulthood in the early backcrosses were
mated with 
 
Gpc3
 
 
 
1
 
/
 
2
 
 mice. The 
 
Gpc3 2/2 female mice
generated in this way displayed a phenotype similar to the
Gpc3 2/ mice. In addition, mutant females had an imper-
forate vagina with higher frequency (30%) than is found in
the normal population (4%; Cunliffe-Beamer and Feld-
man, 1976). As a consequence, these mice experienced
marked swelling of the perineum and the uterus was fluid-
filled, such that it was several times its normal size.
Developmental Overgrowth of Gpc3 2/ Mice
To determine if GPC3-deficient mice exhibit overgrowth,
as SGBS patients do, we compared the weight of Gpc3 2/,
1/2, and 1/1 littermates at different stages of embryonic
development. Fig. 5 shows that the Gpc3 2/ mice were sig-
nificantly heavier than the wild-type littermates at every
time point analyzed. The overgrowth was greater at the
time of birth, when the GPC3-deficient mice were z30%
heavier than normal littermates. Heterozygotes displayed
an intermediate size at all time points. When we compared
heart, lung, and liver weight as percentage of body weight
at different embryonic stages, we found no significant dif-
ferences between Gpc3 1/1 and 2/ mice. Lungs from
Gpc3 2/ mice, however, were disproportionally heavy at
time of birth, weighing 28% more than their normal litter-
mates (data not shown). Since this disproportionate over-
growth is only evident in newborn mice, we speculate that
it is due to the accumulation of debris observed in the
lungs after birth (Fig. 3). With regard to the kidneys, while
those from E13.5 2/ embryos were disproportionally
larger than kidneys from the normal littermates (see Fig.
7), comparison of weight at E16.5, E18.5, and P0 did
not show a statistically significant disproportionate over-
growth. This may be explained by the observation that the
medulla of the 2/ kidneys begins to degenerate by E15.5,
resulting in a reduction in whole kidney mass.
Currently, the molecular basis by which GPC3 regulates
growth is unknown. Based on the phenotypic overlap be-
tween SGBS and BWS, and the fact that biallelic expres-
sion of IGF-II has been associated with BWS, it has been
proposed that GPC3 is a negative regulator of IGF-II
(Pilia et al., 1996). Interestingly, developmental over-
growth of a similar magnitude to that observed in GPC3-
deficient mice has been reported in IGF2R-deficient mice
(Lau et al., 1994; Wang et al., 1994). These mice have in-
creased levels of circulating (about fourfold) and tissue
(about twofold) IGF-II (Lau et al., 1994). This is not sur-
prising, since this receptor binds IGF-II and downregu-
lates its activity by endocytosis and degradation. Thus,
Figure 2. Histological analysis of kidney sections. Kidney sec-
tions from 4-d-old wild-type (top) and GPC3-deficient (bottom)
littermates were fixed and sections stained with hematoxylin and
eosin.Cano-Gauci et al. Gpc3-null Mice Mimic Human SGBS Overgrowth Syndrome 259
to investigate whether the overgrowth observed in the
GPC3-deficient mice could also be due to increased levels
of IGF-II, we measured its serum and tissue levels in wild-
type and Gpc3-mutant mice. As shown in Fig. 6 A, the mu-
tant mice show no significant differences in circulating
IGF-II levels compared with wild-type at developmental
stages in which overgrowth in the GPC3-deficient mice
was documented. We also compared the levels of IGF-II
in protein extracts of whole embryos at E12.5 and E14.5.
As shown in Fig. 6, IGF-II levels were similar in Gpc3 2/
embryos and their normal littermates. Since the levels of
mature IGF-II in embryonic liver, lung, and kidney are too
low to be measured accurately by Western blot, we as-
sessed the levels of IGF-II mRNA in liver, lung, and kid-
ney of E18 embryos by Northern blot. No significant dif-
ference could be detected between Gpc3 2/ and normal
littermates (Fig. 6).
GPC3 Regulates Cell Proliferation in the Developing 
Renal Collecting System
To identify abnormalities that underlie the renal cysts and
dysplasia of Gpc3 2/ mice, embryonic kidneys from N5 to
N8 mice were studied. The E12 normal kidney is charac-
terized by invasion of the blastema by the ureteric bud,
formation of a T-shaped branched ureteric bud, and con-
densation of the blastemal cells around the invading ure-
teric bud (Sorokin and Ekblom, 1992; Fig. 7). Compared
with their normal littermates, E12 2/ kidneys displayed a
larger number of ureteric bud branches (Fig. 7). Develop-
ment of the blastemal compartment in these kidneys was
consistent with the enhanced development of the ureteric
bud component. Quantification of the mass of ureteric
bud, identified by DBA staining in tissue sections using
digitized images, indicated a threefold increase of ureteric
bud surface area in hemizygous null kidneys compared
with wild-type (7,063 6 108 versus 2,380 6 230 arbitrary
units, P , 0.03, two separate litters).
E13.5 Gpc3 2/ kidneys displayed similar abnormalities
to that of E12 kidneys. In addition, they looked signifi-
cantly larger than the kidneys from the normal littermates
(Fig. 7). By E16.5, disruption of tissue development was
evident in the Gpc3 2/ kidneys. While normal looking cor-
tical tissue elements (glomeruli and tubules) were present
Figure 3. Histological analy-
sis of wild-type (1/1) and
GPC3 deficient (2/) lungs.
Hematoxylin and eosin
stained sections of lungs at
E18, P0, and P5 are shown.
Accumulation of mucus (ar-
rowhead) and cellular debris
(arrow) is indicated. Original
magnification is 400.The Journal of Cell Biology, Volume 146, 1999 260
in mutant kidneys, the organization of these elements was
abnormal compared with wild-type. In addition, the tubu-
lar mass in the medulla was reduced. This was accompa-
nied by formation of epithelial cysts (Fig. 7). By E18.5, the
dysplastic appearance of the medulla was fully evident.
Whereas a compact and highly patterned network of tu-
bules was present in the wild-type kidney, the medullary
tubules in Gpc3 2/ kidneys were decreased in number, dis-
organized, and often cystic (Fig. 7).
We hypothesized that a disregulation of cell prolifera-
tion might underlie the accelerated ureteric bud develop-
ment observed in Gpc3 2/ kidneys. Thus, cell proliferation
in the ureteric buds/collecting ducts was assessed by mea-
suring BrdU incorporation into DNA. Quantification of
BrdU uptake in four sets of wild-type and Gpc3 2/ mice at
E12.5 demonstrated a 2.8-fold increase in the percentage
of cells that incorporated BrdU in the epithelial cells of
the collecting system, identified by DBA binding (Fig. 8
A). This enhancement of BrdU uptake in the collecting
system persisted at E13.5 (2.6-fold increase) and E16.5
(3.4-fold increase). In contrast, while the basal rate of cell
proliferation was generally high in mesenchymal cells ad-
jacent to the collecting system (identified by morphology
and lack of staining with DBA), there was no significant
difference in mesenchymal cell proliferation in the kidneys
of Gpc3 1/1 versus Gpc3 2/ mice at E 12.5 (27.6 6 3.0%
versus 30.0 6 1.7%), E13.5 (18.7 6 3.0% versus 24.0 6
1.7%), or E16.5 (21.2 6 2.7% versus 24.3 6 6.4%; four in-
dependent samples, 250 mesenchymal cells counted per
sample).
Taken together, the analysis of cell proliferation in de-
veloping kidneys of Gpc3 2/ mice indicates an early and
persistent abnormality in ureteric bud development due to
increased proliferation of cells intrinsic to this tissue ele-
ment. This observation provides an eloquent example of
the critical role of GPC3 in the regulation of developmen-
tal growth.
Discussion
We report in this paper that GPC3-deficient mice exhibit
several of the clinical features of SGBS patients, including
developmental overgrowth, perinatal death, cystic and dys-
plastic kidneys, and abnormal lung development. Other
abnormalities observed in some SGBS patients, such as
hernias, heart defects, polydactyly, and vertebral and rib
malformations, are not present in the mutant mice. Con-
versely, GPC3-deficient mice display mandibular hypopla-
sia and an imperforate vagina, two clinical features that
have not been described in SGBS patients. It is interesting
to note that an imperforate vagina could be the result of
deficient apoptosis of the vaginal epithelial cells during
sexual maturation (Jacobson et al., 1997). This is consis-
tent with our recent finding that GPC3 can induce apopto-
sis in certain cell types (Dueñas Gonzalez et al., 1998).
Figure 4. Mandibular hypoplasia in Gpc3 2/ embryos. Alizarin
red/Alcian blue skeletal preparations of wild-type (top) and
Gpc3 2/ (bottom) E18.5 embryonic heads are shown. Note the
complete lack of mandible in the mutant embryo.
Figure 5. Embryonic growth kinetics. Wild-type, heterozygous,
and knockout embryos were weighed at the indicated embryonic
day and at birth. Bars represent the average embryo wt 1 2 SEM.
Total number of embryos weighed for each group is indicated
above each bar. Statistical analysis using a t test showed signifi-
cant differences (P , 0.05) between mean weight of the three
genotypes at each time point analyzed, with the exception of
wild-type and heterozygous at P0, and heterozygous and knock-
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Although not all the clinical features observed in SGBS
patients are found in the GPC3-deficient mice, we con-
sider that there are enough similarities to justify the use of
these mice as a model to study SGBS. In particular, these
mice will be useful to study the role of GPC3 in the regula-
tion of growth during development. Indeed, we are report-
ing here that Gpc3 2/ mice display hyperplasia of the de-
veloping ureteric bud/collecting duct system. Most likely
this hyperplasia explains, at least in part, the cystic and
dysplastic phenotype of the kidneys in the GPC3-deficient
mice and SGBS patients. In addition, the GPC3-deficient
mice will be useful to study the role of GPC3 in lung devel-
opment. In this respect, it is interesting to note that SGBS
patients, like the Gpc3 2/ mice, also develop respiratory
infections with high frequency (Garganta and Bodurtha,
1992).
The similarities between SGBS and BWS have sug-
gested the hypothesis that GPC3 regulates IGF-II activity.
Furthermore, the IGF2R-deficient mice display a degree
of developmental overgrowth similar to the Gpc3 2/ mice.
In contrast to the IGF2R knockouts, however, the GPC3-
deficient mice do not show any increase in circulating or
local expression of IGF-II (Fig. 6). Moreover, we have
been unable to detect direct interaction between GPC3
and IGF-II (Song et al., 1997). It can be concluded, there-
fore, that if GPC3 inhibits IGF-II signaling, it does so by a
mechanism that is fundamentally different than the one
used by the IGF2R.
Eggenschwiler et al. (1997) have recently generated
double mutant mice that exhibit a dramatic increase in cir-
culating and tissue IGF-II. These investigators have pro-
posed that, in addition to the clinical features of BWS,
these mice display skeletal abnormalities typical of SGBS
(Table I). However, SGBS patients and GPC3-deficient
mice display severe renal abnormalities, and no such
abnormalities have been found in the double mutant
mice, despite the fact that they express extremely high lev-
els of IGF-II. Moreover, none of the other mice models
that overexpress IGF-II (Igf-II transgenics and Igf2R
knockouts) display any renal alterations. Thus, it is rea-
sonable to propose that even if GPC3 is able to regulate
IGF-II signaling, it may have other functions in addition to
IGF-II regulation. In this regard, we have shown that
GPC3 can bind fibroblast growth factor-2 (Song et al.,
1997), and others have demonstrated that GPC1 can regu-
late the response of several cell types to heparin-binding
growth factors (Steinfeld et al., 1996; Kleef et al., 1998).
Since these interactions are mediated by the glypicans’ HS
chains, it is possible that GPC3 interacts with other factors
that are known to bind to HS, including members of the
transforming growth factor-b and Wnt families. Interest-
ingly, some members of these families are known to play a
role in kidney development (Vainio and Muller, 1997;
Woolf and Cale, 1997).
Recently, it has been reported that z5% of BWS pa-
tients show germline mutations of p57, a cyclin-dependent
kinase inhibitor (Hatada et al., 1996). In addition, it has
been suggested that p57 can also be silenced at the tran-
scriptional level in BWS patients without germline muta-
tions (Lee et al., 1999). Interestingly, p57-deficient mice
show kidney dysplasia, adrenal cytomegaly, and omphalo-
cele, but not overgrowth or other features of BWS patients
(Zhang et al., 1997; Table I). Since mice overexpressing
IGF-II, unlike p57-deficient mice, do not show renal ab-
normalities, it has been proposed that suppression of p57
expression is a key contributor to the phenotype of BWS
patients (Hastie, 1997). This raises the question as to
whether p57 could be mediating some of the signals regu-
lated by GPC3, and this issue should certainly be the sub-
ject of future investigations.
Given the complexity and heterogeneity of the pheno-
Figure 6. Comparative analysis of IGF-II levels in serum, whole
embryo, lung, liver, and kidney. (A) Circulating levels of IGF-II
at different time points during development. (B) Levels of IGF-II
in whole embryos at E12.5 and E14.5. Each bar represents the
mean 1 SEM obtained by densitometric scanning of four pooled
samples done in duplicate. Inset shows a representative image of
the Western blot. (C) IGF-II mRNA levels were measured by
Northern blot analysis and normalized with the intensity of the
corresponding GAPDH band. Each bar represents the mean 1 SEM
obtained by densitometric scanning of two different samples.The Journal of Cell Biology, Volume 146, 1999 262
Figure 7. Kidney develop-
ment in the Gpc3 2/ mouse.
Paraffin-embedded tissue
sections were generated from
fixed tissue isolated from
1/1 and 2/ mice. E12.0 sec-
tions were imaged at 2003.
Bar, 37.5 mm. E13.5, E16.5,
and E18.5 sections were im-
aged at 1003. Bar, 75 mm. At
E12.0, branching of the ure-
teric bud is markedly en-
hanced in the 2/ versus 1/1
embryo (arrowheads). By
E13.5, the 2/ kidney is much
larger than that of its 1/1 lit-
termate and consists of histo-
logically normal ureteric bud
and mesenchymal-derived
tissue elements. While these
mesenchymal-derived ele-
ments (glomeruli and tu-
bules) are present in the cor-
tex (C) of the E16.5 2/ and
1/1 kidneys, they are disor-
ganized in the 2/ cortex and
the 2/ medulla (M) is rela-
tively devoid of tubular
structures. Cysts (Cy) are
present in 2/ medulla in an
irregular pattern. At E18.5,
these abnormalities persist in
the 2/ kidney and are accom-
panied by total absence of
the medullary tubular pat-
terning characteristic of the
1/1 kidney.
Table I. Comparison of Phenotypes
SGBS BWS IGF2R2/2 IGF-II overexpressing p572/2 GPC32/
Overgrowth 11 1 1 2 1
Increased circulating IGF-II ND ND 12 ND 2
Perinatal death 1/21 /21 1 1 1
Kidney dysplasia 1/21 /22 2 1 1
Cardiac defects 1/22 * 11 2 2
Lung abnormalities/infection 1/22 1 /222 1
Polydactyly 1/22 1 1 2 2
Cleft palate 1/22 * 21 1 2
Vertebral abnormalities 1/22 1 1 2 2
Endochondral bone ossification defects 22 2 2 1 2
Macroglossia 1/21 2 1 /22 2
Omphalocele 21 2 1 1 /22
Umbilical hernia 1/21 /22 ND 12
Adrenal cysts 21 2 1 2 2
Adrenal cytomegaly 21 2 2 1 2
1, Observed commonly; 1/2, less commonly observed; 2*, rarely observed; 2, not seen at all; ND, not studied. Data were extracted from the following original reports or re-
views: Garganta et al., 1992; Lau et al., 1994; Wang et al., 1994; Weng et al., 1995; Hughes-Benzie et al., 1996; Ludwig et al., 1996; Eggenschwiler et al., 1997; Yan et al., 1997;
Zhang et al., 1997; Neri et al., 1998.Cano-Gauci et al. Gpc3-null Mice Mimic Human SGBS Overgrowth Syndrome 263
typic features of SGBS and BWS, we consider it unlikely
that the role of the molecules suspected to be involved in
the generation of these disorders will be resolved simply
by genetic manipulation of mice (see Table I). It is evident
that biochemical studies will be required to clarify the con-
nection between the different molecules involved.
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Figure 8. Analysis of cell
proliferation in the renal col-
lecting system of the GPC3-
deficient mice. Incorporation
of BrdU into cells of the ure-
teric buds or collecting ducts,
identified by fluorescein-con-
jugated DBA, was detected
in tissue sections of em-
bryonic kidneys using an
anti-BrdU peroxidase-conju-
gated antibody. (A) Bright-
field (BF) and fluorescence
(IF) images of representative
kidney sections from Gpc3
1/1 and Gpc3  2/ mice at
E12.5 and E16.5. The arrows
mark the position of typical
ureteric buds or collecting
ducts, identified by fluo-
rescein-DBA. BrdU-labeled
cells (brown) are present in
both the collecting system
and in tissue elements de-
rived from the metanephric
blastema, and are more nu-
merous in the cells of the col-
lecting system of the Gpc3 2/
mice. Bar,  18.7  mm (4003).
(B) Quantification of cell
proliferation in the ureteric
buds or collecting ducts in
the kidneys of Gpc3 1/1 and
Gpc3  2/ mice at E12.5,
E13.5, and E16.5. Percent
proliferation was calculated
as the ratio of BrdU-labeled
cells to the total number of
ureteric bud or collecting
duct cells analyzed. Bars rep-
resent the mean 1 SEM.The Journal of Cell Biology, Volume 146, 1999 264
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